Kidney transplant drug dosing gets a closer look

NCT ID NCT01435291

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at how the drug Advagraf (a form of tacrolimus) works in 45 adults who received a kidney transplant. The goal was to find better ways to dose the drug by measuring its levels in the blood right after transplant and three months later. Researchers compared Advagraf with another version of the same drug called Prograf.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Advagraf (tacrolimus prolonged release)
What this could lead to: If successful, this could help doctors give more precise doses of Advagraf to kidney transplant patients, potentially reducing side effects and improving outcomes.
What could go wrong: This is a small, completed pharmacokinetic study, not a large trial testing a new treatment. The findings may not change standard practice or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL TRANSPLANTATION

Contacts and locations

Locations

CHRU Tours Hôpital Bretonneau

Tours, France
CHU de Nice

Nice, 06200, France
CHU de Rangueil

Toulouse, France
Hôpital Bicêtre

Le Kremlin-Bicêtre, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.